Cancer Discovery · 2012 · 51 citations · 29 references
Life SciencesCell BiologyOncologyCell SignalingMolecular OncologySignal TransductionAdhesion MoleculesCancer Cell SignalingOncogenic Signaling PathwaysOvarian CancerOvarian NeoplasiaReceptor Tyrosine Kinase SignalingExtracellular DomainsOvarian Cancer PathogenesisOvarian Surface Epithelial TumorsTherapeutic Growth InhibitionTumor Suppression MechanismsTumor Suppression PathwaysTumor Suppressor LossTumor Suppressor Pathways
UNLABELLED: Epithelial ovarian cancer is the leading cause of death from gynecologic malignancy, and its molecular basis is poorly understood. We previously demonstrated that opioid binding protein cell adhesion molecule (OPCML) was frequently epigenetically inactivated in epithelial ovarian cancers, with tumor suppressor function in vitro and in vivo. Here, we further show the clinical relevance of OPCML and demonstrate that OPCML functions by a novel mechanism in epithelial ovarian cancer cell lines and normal ovarian surface epithelial cells by regulating a specific repertoire of receptor tyrosine kinases: EPHA2, FGFR1, FGFR3, HER2, and HER4. OPCML negatively regulates receptor tyrosine kinases by binding their extracellular domains, altering trafficking via nonclathrin-dependent endocytosis, and promoting their degradation via a polyubiquitination-associated proteasomal mechanism leading to signaling and growth inhibition. Exogenous recombinant OPCML domain 1-3 protein inhibited the cell growth of epithelial ovarian cancers cell in vitro and in vivo in 2 murine ovarian cancer intraperitoneal models that used an identical mechanism. These findings demonstrate a novel mechanism of OPCML-mediated tumor suppression and provide a proof-of-concept for recombinant OPCML protein therapy in epithelial ovarian cancers. SIGNIFICANCE: The OPCML tumor suppressor negatively regulates a specific spectrum of receptor tyrosine kinases in ovarian cancer cells by binding to their extracellular domain and altering trafficking to a nonclathrin, caveolin-1–associated endosomal pathway that results in receptor tyrosine kinase polyubiquitination and proteasomal degradation. Recombinant OPCML domain 1-3 recapitulates this mechanism and may allow for the implementation of an extracellular tumor-suppressor replacement strategy.
29
Functional rafts in cell membranes
Kai Simons, Elina Ikonen · Nature · 1997 · 9.7K citations
Integrated genomic analyses of ovarian carcinoma
Debra Bell, Andrew Berchuck, Narciso Olvera et al. · Nature · 2011 · 8.2K citations · Full text
Chutima Srimaroeng, Jennifer Perry Cecile, Ramsey Walden et al. · Cellular Physiology and Biochemistry · 2013 · 3K citations · Full text
Characterization and properties of nine human ovarian adenocarcinoma cell lines.
Simon P. Langdon, S. S. Lawrie, F G Hay et al. · PubMed · 1988 · 268 citations